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Abstract: Pembrolizumab is an immune checkpoint inhibitor (ICI), currently recommended as the
first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) showing ≥50%
expression of programmed death-ligand 1 (PD-L1). Previously it was reported that platinum-based
chemotherapy may change PD-L1 expression in solid cancers. However, no reports addressing
alteration of PD-L1 expression after ICI therapy in NSCLC are available so far. The patients were
Japanese males 83 and 87 years old, who were diagnosed with NSCLC based on the transbronchial lung
biopsies showing sarcomatoid feature with high PD-L1 expression. They received Pembrolizumab,
however, passed away with disease progression on day 27 and day 9, respectively. PD-L1, PD1, and CD8
antibodies were applied to pretreatment tumor biopsies and autopsy specimens. Immunoexpression
of all the markers was evaluated using Aperio ImageScope. We found that PD-L1 expression decreased
significantly from 75.6% to 13.2% and from 100% to 58.8%, in patients 1 and 2, respectively. This
alteration was less prominent in the perinecrotic tumor area. A considerable decrease of PD-L1 score
was linked with a little effect of Pembrolizumab in our patients. This association might be one of the
contributing mechanisms of resistance to ICI and needs further investigation in large-scale studies.
Keywords: NSCLC; immune therapy; Pembrolizumab; immune checkpoint inhibitors; PD-L1;
tumor microenvironment
1. Introduction
Lung cancer is the leading cause of cancer-related death worldwide. Non-small-cell lung
cancer (NSCLC) accounts for approximately 80% of all lung cancer cases [1]. Introduction of
immune checkpoint inhibitor (ICI) therapy significantly improved progression-free and overall
survival of patients with NSCLC compared with conventional platinum-based chemotherapy. ICIs,
such as Pembrolizumab, are currently recommended as frontline treatment in patients with advanced
epidermal growth factor receptor (EGFR) mutations/anaplastic lymphoma kinase (ALK) gene fusions,
ROS proto-oncogene 1 (ROS1) gene fusions, and B-Raf proto-oncogene (BRAF) gene mutations
wild-type NSCLC and programmed death-ligand 1 (PD-L1) tumor proportion score ≥50% [2,3].
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Programmed cell death protein 1 (PD-1) is one of the coinhibitory receptors expressed on the surface of
antigen-stimulated T cells. PD-L1 and PD-L2 are its ligands on the surface of tumor cells [4].
Numerous reports on lung and other solid cancers showed that PD-L1 expression can be
altered after platinum-based chemotherapy or concurrent chemoradiation [5]. In a representative
series, Fujimoto et al. showed that PD-L1 expression significantly decreased after the concurrent
chemoradiation therapy in locally advanced non-small lung cancer, which was associated with
favorable prognosis [6]. In the trial, the median overall survival of patients with decreased, unchanged,
or increased PD-L1 expression was 85.1, 92.8, and 14.6 months, respectively [6]. Interestingly, despite
direct link between PD-L1 and ICI, no reports on dynamics of PD-L1 expression after ICI therapy in
lung cancer are available.
We present two patients of NSCLC with fatal outcome, which failed to respond to Pembrolizumab.
Both cases showed altered PD-L1 expression of tumor cells and immune cells distribution after ICI
administration. We speculate that there is a possible association between the alteration of PD-L1
expression and ICI treatment outcome in patients with NSCLC.
2. Results
2.1. Case 1
An 83-year-old male with a 40 pack-year smoking status and no relevant medical history
was admitted to our hospital presenting exertional dyspnea for two weeks. He also complained
about his right upper back pain and unintentional weight loss. On admission, his performance
status, according to the Eastern Cooperative Oncology Group, was 3, and his vital signs were
normal and physical examination was remarkable for decreased breath sounds on the right side
of the chest. Contrast computed tomography (CT) scan showed right contrast-enhanced pleural
thickness with massive pleural effusion (Figure 1A,B). 18F-fluorodeoxyglucose-positron emission
tomography (FDG-PET) showed high FDG uptake in the thickened right pleura and mediastinal
and cervical lymph nodes (Figure 1C,D). He was suspected of having malignant mesothelioma and
received CT-guided pleuropulmonary biopsy. Pathological diagnosis based on microscopic and
immunohistochemical findings was poorly differentiated non-small-cell carcinoma with sarcomatoid
differentiation (Figure 1E,F). The clinical stage as per the 8th edition AJCC/TNM was T4N3M1c
(stage IVB). Molecular studies detected no ALK rearrangement and EGFR mutation. Immunostaining
with anti-PD-L1 revealed high PD-L1 expression; a tumor proportion score (TPS) after the manual
evaluation was reported as 65%.
The patient was treated with ICI Pembrolizumab (200 mg per course/body). At day 8, his white
blood cell count increased up to 36,300/µL. His respiratory status was initially improved but his
condition gradually got worse. At day 15, chest CT revealed increased circumferential thickness of
right pleura and increased amount of pleural effusion. His status was considered as progressive
disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and the
next administration of Pembrolizumab was postponed. The patient passed away at day 28 due to
multiple organ failure. Postmortem CT showed lobular consolidation in both lungs (Figure 1G,H).
Autopsy revealed medullary variegated hemorrhagic–necrotic cancer encasing the whole right lung,
suggesting the pseudomesotheliomatous lung cancer, with metastasis to lymph nodes, adrenal glands,
and vertebral column.
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Figure 1. Imaging and histopathological findings in case 1. Chest computed tomography showing 
tumor (yellow outline) before ICI treatment on mediastinal (A) and lung (B) window images. PET-
CT scan found high FDG uptake in the thickened right pleura (C), mediastinal and cervical lymph 
nodes (D, white arrowhead). Hematoxylin & eosin staining revealed poorly differentiated carcinoma, 
200× (E). Immunostaining with TTF-1 demonstrated only focal residual expression, 200× (F). 
Postmortem chest tomography showed significantly increased circumferential pleural thickness (blue 
arrowhead) on mediastinal (G) and lung (H) window images. 
Figure 1. Imaging and histopathological findings in case 1. Chest computed tomography showing
tumor (yellow outline) before ICI treatment on mediastinal (A) and lung (B) window images. PET-CT
scan found high FDG uptake in the thickened right pleura (C), mediastinal and cervical lymph nodes
(D, white arrowhead). Hematoxylin & eosin staining revealed poorly differentiated carcinoma, 200×
(E). Immunostaining with TTF-1 demonstrated only focal residual expression, 200× (F). Postmortem
chest tomography showed significantly increased circumferential pleural thickness (blue arrowhead)
on mediastinal (G) and lung (H) window images.
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2.2. Case 2
An 86-year-old male, who had 60 pack-year smoking status and no relevant medical history,
was admitted to our hospital presenting hematochezia. His performance status was 3 and his vital
signs and physical exam were unremarkable. CT detected a mass lesion in S6 of the right lung
(Figure 2A,B). FDG-PET scan showed high tracer uptake in the right hilar region and in the liver
(Figure 2C,D), suggesting local progression and systemic metastasis. Transbronchial biopsy revealed
poorly differentiated squamous cell carcinoma positive for TTF-1 and negative for p40. The patient
was diagnosed as squamous cell carcinoma (cT2aN0M0, stage IB) and underwent lobectomy of the
right lower lobe with mediastinal lymph node dissection. Histopathological examination of the
surgical specimen showed spindle cells and giant cells (Figure 2E,F), which was consistent with
pleomorphic carcinoma with no evidence of lymph node metastasis (pT3N0M0, stage IIB). The tumor
was negative for ALK rearrangements, and EGFR and ROS-1 mutations. No adjuvant chemotherapy
was administered.
Three months after the surgery, PET-CT revealed local recurrence and systemic metastases
at the follow-up visit. Additional immunostaining of the surgical tumor specimen showed high
PD-L1 expression with 90% TPS after manual evaluation, and therefore the patient was treated with
Pembrolizumab (200 mg/body). During the treatment, his white blood cell count elevated up to
61,100/µL on day 3. He passed away on day 9 due to respiratory failure. Postmortem CT showed
the right bronchial invasion of the tumor causing the collapse of the right lung and the massive right
pleural effusion (Figure 2G,H). An autopsy revealed the local recurrence of the carcinoma involving
the hilar area of the right upper lobe. The cancer spread to the right adrenal, liver, and paraaortic
abdominal lymph nodes.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 10 
 
 
Figure 2. Imaging and microscopic findings in case 2. Computed tomography scan of the chest 
showing tumor (yellow outline) before ICI treatment on mediastinal (A) and lung (B) window images. 
PET-CT scan found high FDG uptake in the mass located in right hilar region (C, white arrowhead) 
and in the liver (D, white arrow). Routine hematoxylin & eosin staining revealed pleomorphic 
carcinoma with giant and spindle cells, 200× (E). Immunostaining with TTF-1 demonstrated loss of 
expression in the most carcinoma cells and residual expression in the entrapped bronchial and 
alveolar epithelium, 200× (F). Postmortem chest scan showed increased amount of pleural effusion 
(asterisk) and bilateral consolidation (blue arrowhead) on mediastinal (G) and lung (H) window 
images. 
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Figure 2. Imaging and microscopic findings in case 2. Computed tomography scan of the chest showing
tumor (yellow outline) before ICI treatment on ediastinal (A) and lung (B) window images. PET-CT
scan found high FDG uptake in the mass located in right hilar region (C, white arrowhead) and in
the liver (D, white arrow). Routine hematoxylin & eosin staining revealed pleomorphic carcinoma
with giant and spindle cells, 200× (E). Immunostaining with TTF-1 demonstrated loss of expression in
the most carcinoma cells and residual expression in the entrapped bronchial and alveolar epithelium,
200× (F). Postmortem chest scan showed increased amount of pleural effusion (asterisk) and bilateral
consolidation (blue arrowhead) on mediastinal (G) and lung (H) window images.
2.3. Immunohistochemical Findings
In both cases, pathological findings were remarkable for the altered PD-L1 expression that turned
from high into low to moderate (Figure 3). Digital image analysis revealed that PD-L1 expression
significantly decreased in both cases, particularly in the viable tumor area (Table 1). PD-1 switched from
completely negative expression to occasionally positive. CD8-positive cells tended to infiltrate more in
the viable tumor area after ICI course. However, there was an opposite trend in the perinecrotic area.
Table 1. Immunohistochemical expression of PD-L1 and selected biomarkers in non-small-cell lung





Viable Tumor Area Perinecrotic Area
Patient 1
PD-L1 75.6% 13.2% 31.7%
PD-1 0.0% 0.7% 0.3%
CD8 6.3 10.1 6.6
Patient 2
PD-L1 100.0% 58.8% 79.7%
PD-1 0.0% 4.5% 1.2%
CD8 21.5 28.8 4.4
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3. Discussion
In this study, we found the expr ssion of PD-L1 on tumor cells turned from high to low and the
trend that viable cells showed less expression than necrotic cells. Evaluation of biopsy samples after
the I I therapy is not a common practice, and we believe this is the first study to demonstrate the
alteration of PD-L1 expression after the ICI therapy. This investigation showed the possibility that the
alteration of the PD-L1 expression is associated with the failure of ICI therapy.
Mechanism of action of ICI is associated with the reactivation and clonal proliferation of
antigen-exposed T cells [7]. Antigen-presenting cells, such as dendritic cells and B cells, present
tumor-associated peptide antigens and T cell receptors of naïve T cells recognize these peptides
displayed by major histocompatibility complex, which initiate activation of T cells. Blockade of the
PD-1 signaling axis prevents PD-1-mediated attenuation of proximal T cell receptor signaling, allowing
for restoration of activity of immune cells [8].
In our two autopsy cases, the expression of PD-L1 decreased remarkably after the ICI administration
(Figure 3), which could be related to the potential mechanism of failure of the ICI therapy.
The mechanism of resistance to anti-PD-1/PD-L1 therapy is not fully understood. Several contributing
factors including tumor neoantigen expression, the switch of cellular signaling pathways, tumor
microenvironment (TME), and epigenetic modification were reported [5]. Even if tumor-specific
antigens are presented on the surface of the cancer cells, ICI does not work effectively if the function of
the activated T cells is inadequate or exhausted [9]. Particularly, failure of ICI therapy can be associated
with inadequate generation of antitumor T cells, inadequate functions of activated T cells, and impaired
function of T cell memory [7].
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The TME also plays a key role in the efficacy of ICI therapy. Various factors are involved in the TME.
Major players include myeloid cells, cytokines, Foxp3+CD4+ regulatory T cells, and cancer-associated
fibroblasts [10]. Regulatory T cells exert an inhibitory effect by inducing various cytokines and directly
inhibiting T cell proliferation. The response to ICI therapy was associated with the increased ratio of
effector T cells to regulatory T cells [11]. In terms of the TME, one of the important mechanisms of
resistance is upregulation of PD-1 ligands in the TME and connection of the PD-L1 to CD8+ T cells [11].
Encountering tumor antigen prompts infiltrated CD8-positive T cells to secrete IFN-γ which leads to
the upregulation of PD-L1 in tumor cells [12].
In our cases, a significant decrease in PD-L1 expression was accompanied by tumor progression
in a short period. Contrast CT showed that the tumor volume increased several times in both cases
(Figures 1A,G and 2A,G), thus various mechanisms such as low response of ICI therapy, the exhaustion
of T cells, and the high rate of tumor proliferation based on the histological feature (pleomorphic
feature) could be hypothesized.
There are a few studies which reported the dynamics of PD-L1 expression by cancer cells in
patients with NSCLC treated with chemotherapy. Fujimoto et al. found that decrease of the PD-L1
expression after the concurrent chemoradiation therapy was related to the favorable prognosis [6].
Sheng et al. also showed the negative-to-positive switch of PD-L1 status was significantly associated
with poor prognosis [13]. Another study reported a significant decrease of PD-L1 expression in patients
with NSCLC treated with cisplatin-based chemotherapy but did not evaluate any correlation with
outcome [5]. On the other hand, two independent Japanese groups demonstrated the opposite results.
Omori et al. found that patients with NSCLC treated with EGFR tyrosine kinase inhibitors showed
increase in PD-L1 expression, though no obvious correlation of increase or decrease of PD-L1 expression
and survival was drawn [14]. The most recent study reported that PD-L1 expression tended to be
increased in rebiopsy samples compared with the initial biopsy in patients with NSCLC wild-type for
EGFR mutations and ALK rearrangement who underwent cytotoxic chemotherapy [15]. In summary,
existing data on the change of PD-L1 expression in response to chemotherapy are conflicting, and there
has been no reported clear association between such alteration and prognosis.
The issue of the change of PD-L1 expression on tumor cells due to ICI therapy has not been
addressed so far. Intuitively, we would assume that PD-L1 expression remains high or unchanged in
patients who responded to the ICI therapy, and it may likely decrease in the patients who failed the
therapy. As it is recommended that ICI is administered to the NSCLC patients with PD-L1 expression
over 50%, the more PD-L1 expressed on tumor cells, the more effective the ICI response [3]. It was
shown that the lower PD-L1 expression is linked with the less efficient ICI therapy [16]. Therefore,
a dynamic decrease of PD-L1 expression during ICI treatment might be considered to negatively
correlate with the treatment success.
In order to evaluate PD-L1 expression in the context of the TME, we focused on two geographic
zones, including viable tumor area and perinecrotic area. We observed the alteration of PD-L1
expression in both zones. The area populated with survived tumor cells showing relatively lower
expression of PD-L1 was thought to be “resistant” to ICI therapy, while the perinecrotic area showing
higher PD-L1 expression compared to the viable area was thought to be “sensitive” to ICI therapy.
One of the reasons for alteration in both areas might be less stimulation of PD-1 to PD-L1 which
downregulates PD-L1 expression. To address TME-related perturbations, immunostaining with PD-1
and CD8 antibodies was performed. PD-1 expression slightly increased but such change might not be
significant. One of the possible contributing mechanisms is that PD-1 molecule was “masked” due to
binding between PD-1 and PD-1 inhibitor. Percentage of CD8+ T cells slightly increased in the viable
tumor area. Theoretically, CD8+ T cells are prompted to infiltrate into the tumor interface, and it was
reported that PD-1 inhibitor increased the intratumor CD8/Treg ratio [17]. In the murine model of
breast cancer, neoadjuvant ICI therapy resulted in a sustained increase of tumor-specific CD8+ T cells
in the blood, which predicted long-term survival [18]. In summary, changes in PD-1 expression and
infiltration by CD8 cells were rather insignificant compared to the dynamics of PD-L1.
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This study has some limitations which need to be considered in the future larger-scale studies.
For instance, heterogeneity of PD-L1 expression in cancer cells, which is caused by the polyclonal
evolution of the tumor [19] and also influenced by TME [20], may be challenging for scoring. In the same
sense, an autopsy sample of the tumor may not exactly match an area of tumor tissue obtained by biopsy
before the ICI therapy, which can be considered as an inherent limitation. PD-L1 heterogeneity often
creates difficulties in the evaluation, which lays a foundation for interobserver variation. To overcome
this obstacle, we employed an automated digital image analysis. It was not surprising to find that the
manual score of PD-L1 expression showed a certain discordance (about 10% lower TPS) compared to
the automated scoring. There is a current trend to implement digital image analysis in the workflow of
PD-L1 protocols [21].
4. Materials and Methods
4.1. Immunohistochemistry
Immunostaining was performed on formalin-fixed, paraffin-embedded whole tissue sections
using antibodies specific to PD-L1 (clone 22C3; prediluted, Agilent, Palo Alto, CA, USA), PD-1
(1:50; Abcam, Cambridge, UK), and CD8 (clone C8/144B; prediluted, Nichirei, Tokyo, Japan).
Tissue blocks containing the most representative and well-preserved tumor areas were selected
for immunostaining. Four-micrometer-thick sections were positioned on positively charged slides,
dewaxed in xylene, and rehydrated using graded alcohols. The whole staining procedure from
blocking to counterstaining was performed on Dako Autostainer Link 48 (Dako, Carpinteria, CA, USA)
according to the manufacturers’ protocols.
4.2. Evaluation of Immunostaining and Digital Image Analysis
All slides stained with the antibodies to PD-L1, PD-1, and CD8 were digitized by MoticEasyScan
digital slide scanner (Motic, Hong Kong, China) on ×40 magnification. Image analysis was performed
using the Aperio Imagescope v.12.1.0.5029 software package (Aperio Technologies, Inc., Vista, CA,
USA). Immunostaining was automatically scored using the commercially available Nuclear v.9 and
Membranous v.9 algorithms (Aperio Technologies, Inc., USA). The membranous algorithm was applied
to score PD-L1 expression and the nuclear algorithm was used for PD-1 and CD8 immunostains. PD-L1
was evaluated in all cancer cells and the tumor proportion score was defined as the percentage of
viable tumor cells showing partial or complete membrane staining (≥1%) relative to all viable tumor
cells present in the sample (positive and negative) [22]. PD-1 and CD8 were scored in hot spots.
The quantification of the CD8+ T cells was accomplished by calculating the number of the CD8+ T cells
per area of 0.6 mm2.
Expression of the target proteins was analyzed in two areas of the tumor. Major was the area
occupied by the viable cancer cells (i.e., resistant to ICI therapy). In addition, we separately evaluated
the perinecrotic area, which is supposed to represent alive but degenerating cancer cells.
5. Conclusions
We reported two autopsy cases with dynamic alteration of PD-L1 expression after administering
ICI. This observation might be one of the contributing mechanisms to the ICI resistance. Currently
there are numerous ongoing clinical trials of neoadjuvant ICI therapy in various malignancies, however,
there have been no reports on the correlation between alteration of PD-L1 expression after ICI therapy
and its outcome. We believe that monitoring of PD-L1 expression during the treatment to seek the
better outcome of the ICI therapy deserves further detailed investigation.
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Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung
cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [CrossRef] [PubMed]
3. Vignot, S. NCCN Clinical Practice Guideline: Non-small Cell Lung Cancer. Oncologie 2006, 8, 643–646.
[CrossRef]
4. Sun, C.; Mezzadra, R.; Schumacher, T.N. Regulation and function of the PD-L1 checkpoint. Immunity 2018,
48, 434–452. [CrossRef]
5. Rojkó, L.; Reiniger, L.; Téglási, V.; Fábián, K.; Pipek, O.; Vágvölgyi, A.; Agócs, L.; Fillinger, J.; Kajdácsi, Z.;
Tímár, J.; et al. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
J. Cancer Res. Clin. Oncol. 2018, 144, 1219–1226. [CrossRef] [PubMed]
6. Fujimoto, D.; Uehara, K.; Sato, Y.; Sakanoue, I.; Ito, M.; Teraoka, S.; Nagata, K.; Nakagawa, A.; Kosaka, Y.;
Otsuka, K.; et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation
therapy in non-small cell lung cancer patients. Sci. Rep. 2017, 7, 2–11. [CrossRef]
7. Jenkins, R.W.; Barbie, D.A.; Flaherty, K.T. Mechanisms of resistance to immune checkpoint inhibitors.
Br. J. Cancer 2018, 118, 9–16. [CrossRef] [PubMed]
8. Wei, S.C.; Duffy, C.R.; Allison, J.P. Fundamental mechanisms of immune checkpoint blockade therapy.
Cancer Discov. 2018, 8, 1069–1086. [CrossRef]
9. O’Donnell, J.S.; Long, G.V.; Scolyer, R.A.; Teng, M.W.; Smyth, M.J. Resistance to PD1/PDL1 checkpoint
inhibition. Cancer Treat. Rev. 2017, 52, 71–81. [CrossRef]
10. Boes, M. Cancer immunotherapy: Moving beyond checkpoint inhibition. Oncotarget 2018, 9, 1–21. [CrossRef]
11. Bai, J.; Gao, Z.; Li, X.; Dong, L.; Han, W.; Nie, J. Regulation of PD-1/PD-L1 pathway and resistance to
PD-1/PDL1 blockade. Oncotarget 2017, 8, 110693–110707. [CrossRef]
12. Wang, Y.; Zhu, C.; Song, W.; Li, J.; Zhao, G.; Cao, H. PD-L1 Expression and CD8+ T cell infiltration predict a
favorable prognosis in advanced gastric cancer. J. Immunol. Res. 2018, 4180517. [CrossRef] [PubMed]
13. Sheng, J.; Fang, W.; Yu, J.; Chen, N.; Zhan, J.; Ma, Y.; Yang, Y.; Huang, Y.; Zhao, H.; Zhang, L. Expression of
programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
Sci. Rep. 2016, 6, 1–10. [CrossRef]
14. Omori, S.; Kenmotsu, H.; Abe, M.; Watanabe, R.; Sugino, T.; Kobayashi, H.; Nakashima, K.; Wakuda, K.;
Ono, A.; Taira, T.; et al. Changes in programmed death ligand 1 expression in non-small cell lung cancer
patients who received anticancer treatments. Int. J. Clin. Oncol. 2018, 23, 1052–1059. [CrossRef] [PubMed]
15. Sakai, H.; Takeda, M.; Sakai, K.; Nakamura, Y.; Ito, A.; Hayashi, H.; Tanaka, K.; Nishio, K.; Nakagawa, K.
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non–small cell lung cancer negative
for EGFR mutation and ALK fusion. Lung Cancer 2019, 127, 59–65. [CrossRef] [PubMed]
16. Aguilar, J.E.; Rizvi, H.; Kravets, S.; Lydon, C.; Adeni, A.; Subegdjo, S.; Hellmann, M.; Awad, M. Comparison
of outcomes with PD-L1 tumor proportion score (TPS) of 50–74% vs. 75–100% in patients with non-small cell
lung cancer (NSCLC) treated with first-line PD-1 inhibitors. J. Clin. Oncol. 2018, 36, 9037. [CrossRef]
17. Curran, M.A.; Montalvo, W.; Yagita, H.; Allison, J.P. PD-1 and CTLA-4 combination blockade expands
infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl.
Acad. Sci. USA 2010, 107, 4275–4280. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 2578 10 of 10
18. Liu, J.; Blake, S.J.; Yong, M.C.; Harjunpää, H.; Ngiow, S.F.; Takeda, K.; Young, A.; O’Donnell, J.S.; Allen, S.;
Smyth, M.J.; et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate
metastatic disease. Cancer Discov. 2016, 6, 1382–1399. [CrossRef]
19. Bassanelli, M.; Sioletic, S.; Martini, M.; Giacinti, S.; Viterbo, A.; Staddon, A.; Liberati, F.; Ceribelli, A.
Heterogeneity of PD-L1 expression and relationship with biology of NSCLC. Anticancer Res. 2018,
38, 3789–3796. [CrossRef]
20. Junttila, M.R.; de Sauvage, F.J. Influence of tumour micro-environment heterogeneity on therapeutic response.
Nature 2013, 501, 346–354. [CrossRef]
21. Taylor, C.R.; Jadhav, A.P.; Gholap, A.; Kamble, G.; Huang, J.; Gown, A.; Doshi, I.; Rimm, D.L.
A Multi-institutional study to evaluate automated whole slide scoring of immunohistochemistry for
expression in non-small cell lung cancer. Appl. Immunohistochem. Mol. Morphol. 2019, 27, 263–269. [CrossRef]
[PubMed]
22. PD-L1 IHC 22C3 pharmDx Interpretation Manual—NSCLC; Agilent Technologies, Inc.: Santa Clara, CA, USA,
2018; pp. 1–76.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
